首页> 外文期刊>Journal of Medicinal Chemistry >Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1)
【24h】

Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1)

机译:吲哚衍生物作为单羧酸转运蛋白 1 (MCT1;SLC16A1)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The solute carrier (SLC) monocarboxylate trans-porter 1 (MCT1; SLC16A1) represents a promising target for the treatment of cancer; however, the MCT1 modulator landscape is underexplored with only roughly 100 reported compounds. To expand the knowledge about MCT1 modulation, we synthesized a library of 16 indole-based molecules and subjected these to a comprehensive biological assessment platform. All compounds showed functional inhibitory activities against MCT1 at low nanomolar concentrations and great antiproliferative activities against the MCT1-expressing cancer cell lines A-549 and MCF-7, while the compounds were selective over MCT4 (SLC16A4). Lead compound 24 demonstrated a greater potency than the reference compound, and molecular docking revealed strong binding affinities to MCT1. Compound 24 led to cancer cell cycle arrest as well as apoptosis, and it showed to sensitize these cancer cells toward an antineoplastic agent. Strikingly, compound 24 had also significant inhibitory power against the multidrug transporter ABCB1 and showed to reverse ABCB1-mediated multidrug resistance (MDR).
机译:溶质载体(SLC)单羧酸转运蛋白1(MCT1;SLC16A1)是治疗癌症的一个有前途的靶点;然而,MCT1 调节剂的前景尚未得到充分探索,只有大约 100 种已报道的化合物。为了扩展有关 MCT1 调节的知识,我们合成了一个包含 16 个基于吲哚的分子的库,并将它们置于一个全面的生物学评估平台中。所有化合物在低纳摩尔浓度下均对 MCT1 具有功能抑制活性,对表达 MCT1 的癌细胞系 A-549 和 MCF-7 具有较强的抗增殖活性,而对 MCT4 具有选择性 (SLC16A4)。先导化合物 24 显示出比参比化合物更高的效力,分子对接显示与 MCT1 具有很强的结合亲和力。化合物 24 导致癌细胞周期停滞和细胞凋亡,并且它显示使这些癌细胞对抗肿瘤剂敏感。引人注目的是,化合物 24 对多药转运蛋白 ABCB1 也具有显着的抑制力,并显示出逆转 ABCB1 介导的多药耐药性 (MDR)。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号